Patents Assigned to Amura Limited
  • Patent number: 8933109
    Abstract: A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein: one of R3 and R4 is H, and the other is selected from C1-6-alkyl, C1-6-haloalkyl, C1-6-alkoxy, and C6-12-aralkyl; or R3 and R4 are each independently selected from C1-6-alkyl and halo; R9 is a substituted 5 or 6-membered aryl or heteroaryl group or a 6,5- or 6,6-fused biaryl or heterobiaryl group. Compounds of formula (I) exhibit surprisingly high efficacies for human cathepsin S, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, Sjogrens syndrome, Grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: January 13, 2015
    Assignee: Amura Limited
    Inventors: Martin Quibell, John Paul Watts, Nicholas Sean Flinn
  • Patent number: 7247622
    Abstract: An oxapenem compound which is, or is capable of forming, a zwitterion of formula wherein R is a C1-C8 branched or straight chain alkyl group which is substituted by a protonated nitrogen base. The compounds find particular use as high bioavailability ?-lactamase inhibitors.
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: July 24, 2007
    Assignee: Amura Limited
    Inventors: Hans Rudolf Pfaendler, Iain Nelson Simpson